Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Cladribine
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Cognitive impairment in multiple sclerosis.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Differential roles of microglia and monocytes in the inflamed central nervous system.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Sanofi MS drug nears green light after pass-the-parcel marathon
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.

Pages